Bcl-2 and Bax expression and chlorambucil-induced apoptosis in the T-cells and leukaemic B-cells of untreated B-cell chronic lymphocytic leukaemia patients

Leukemia Research

Volumn 24, Issue 10, 2000, Pages 813-821

  Thomas, Alun ^a   Pepper, Chris ^a   Hoy, Terry ^b   Bentley, Paul ^a  

^a LLANDOUGH HOSPITAL   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Apoptosis; B cell chronic lymphocytic leukaemia; Bax; Bcl 2; Chlorambucil; T cells

Indexed keywords

CHLORAMBUCIL; PROTEIN BAX; PROTEIN BCL 2;

APOPTOSIS; ARTICLE; B CELL LEUKEMIA; CHEMOSENSITIVITY; CHEMOTHERAPY; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IMMUNOSTIMULATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE;

ANTINEOPLASTIC AGENTS, ALKYLATING; APOPTOSIS; B-LYMPHOCYTES; BCL-2-ASSOCIATED X PROTEIN; CELLS, CULTURED; CHLORAMBUCIL; HUMANS; LEUKEMIA, B-CELL, CHRONIC; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; T-LYMPHOCYTES;

EID: 0033839403     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(00)00051-5     Document Type: Article

References (37)

1. Catovsky D., Miiani E., Okos A., Galton D. Clinical significance of T-cells in chronic lymphocytic leukaemia. Lancet. 2:1974;751.
2. Platsoukas C.D., Galinski M., Kempin S., Reich L., Clarkson B., Good R.A. Abnormal T lymphocyte subpopulations in patients with B-cell chronic lymphocytic leukemia: an analysis by monoclonal antibodies. J. Immunol. 129:1982;2305.
3. Kay N.E., Johnson J.D., Stanek R., Douglas S.D. T-cell subpopulations in chronic lymphocytic leukemia: abnormalities in distribution and in vitro receptor maturation. Blood. 54:1979;540.
4. Totterman T.H., Carlsson M., Simonsson B., Bengtsson M., Nilsson K. T-cell activation and subset patterns are altered in B-CLL and correlate with the stage of the disease. Blood. 74:1989;786.
5. Peller S., Kaufman S. Decreased CD45RA T cells in B-cell chronic lymphatic leukemia patients: correlation with disease stage. Blood. 78:1991;1569.
6. Zaknoen S.L., Kay N.E. Immunoregulatory cell dysfunction in chronic B-cell leukemias. Blood Rev. 4:1990;165.
7. Frovlova E.A., Richards S.J., Jones R.A., Rawstron A., Master P.S., Teasdale J. et al. Immunophenotypic and DNA genotypic analysis of T-cell and NK-cell subpopulations in patients with B-cell chronic lymphocytic leukaemia (B-CLL). Leuk. Lymphoma. 16:1995;307.
8. Rossi E., Matutes E., Morilla R., Owusu-Ankomah K., Heffernan M., Catovsky D. Zeta chain and CD28 are poorly expressed on T lymphocytes from chronic lymphocytic leukemia. Leukemia. 10:1996;494.
9. Bartik M.M., Welker D., Kay N.E. Impairments in immune cell function in B cell chronic lymphocytic leukemia. Semin. Oncol. 25:1998;27.
10. Strasser A. Life and death during lymphocyte development and function: evidence for two distinct killing mechanisms. Curr. Opin. Immunol. 7:1995;228.
11. Wong B., Choi Y. Pathways leading to cell death in T cells. Curr. Opin. Immunol. 9:1997;358.
12. Cory S. Regulation of lymphocyte survival by the Bcl-2 gene family. Annu. Rev. Immunol. 13:1995;513.
13. Oltvai Z.N., Milliman C.L., Korsmeyer S.J. Bcl-2 heterodimerizes in vitro with a conserved homolog, Bax, that accelerates programmed cell death. Cell. 74:1993;609.
14. Hanada M., Delia D., Aiello A., Stadtmauer E., Reed J.C. Bcl-2 gene hypomethylation and high level expression in B-cell chronic lymphocytic leukemia. Blood. 82:1993;1820.
15. Reed J. Molecular biology of chronic lymphocytic leukemia: implications for therapy. Semin. Haematol. 35:1998;3.
16. Robertson L.E., Plunkett W., McConnell Y., Keating M.J., McDonnell T.J. Bcl-2 expression in chronic lymphocytic leukemia and its correlation with the induction of apoptosis and clinical outcome. Leukemia. 10:1996;456.
17. Aguilar-Santelises M., Rottenberg M.E., Lewin N., Mellstedt H., Jondal M. Bcl-2, Bax and p53 expression in B-CLL in relation to in vitro survival and clinical progression. Int. J. Cancer. 69:1996;114.
18. Pepper C., Hoy T., Bentley P. Bcl-2/Bax ratios in chronic lymphocytic leukaemia and their correlation with in vitro apoptosis and clinical resistance. Br. J. Cancer. 76:1997;935.
19. Kitada S., Andersen J., Akar S., Zapata J.M., Takayama S., Krajewski S. et al. Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with in vitro and in vivo chemoresponses. Blood. 91:1998;3379.
20. Johnston J.B., Daeninck P., Verburg L., Lee K., Williams G., Israels L.G., Mowat M., Begleiter A. P53, mdm2, Bax and Bcl-2 and drug resistance in chronic lymphocytic leukemia. Leuk. Lymphoma. 26:1997;435.
21. Bergmann L., Fenchel K., Jahn B., Mitrou P.S., Hoelzer D. Immunosuppressive effects and clinical response of fludarabine in refractory chronic lymphocytic leukemia. Ann. Oncol. 4:1993;371.
22. Binet J.L., Auquier A., Dighiero G., Chastang C., Piguet H., Goasguen J. et al. A new prognostic classification of chronic lymphocytic leukemia derived from multivariate survival analysis. Cancer. 48:1981;198.
23. Pepper C., Thomas A., Hoy T., Bentley P. Chlorambucil resistance in B-cell chronic lymphocytic leukaemia is mediated through failed Bax induction and selection of high Bcl-2-expressing subclones. Br. J. Haematol. 104:1999;581.
24. Vermes I., Haanen C., Steffens-Nakken R., Reutelingsperger C. A novel assay for apoptosis: flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J. Immunol. Methods. 184:1995;39.
25. Aggarwal S., Gupta S. Increased apoptosis of T cell subsets in ageing humans: altered expression of Fas (CD95), Fas ligand, Bcl-2 and Bax. J. Immunol. 160:1998;1627.
26. Wen T., Mellstedt H., Jondal M. Presence of clonal T cell populations, in chronic B lymphocytic leukemia and smouldering myeloma. J. Exp. Med. 171:1990;659.
27. Farace F., Orlanducci F., Dietrich P.-Y., Gaudin C., Angevin E., Courtier M.-R. et al. T cell repertoire in patients with B chronic lymphocytic leukemia. J. Immunol. 153:1994;4281.
28. Alatrakchi N., Farace F., Frau E., Carde P., Munck J.-N., Triebel F. T-cell clonal expansion in patients with B-cell lymphoproliferative disorders. J. Immunother. 21:1998;363.
29. Rassenti L.Z., Bessudo A., Tsai A., Kipps T.J. Analysis of the repertoire expressed by the T cells of patients with chronic lymphocytic leukemia pre and post chemotherapy. Blood. 92(Suppl 1):1998;432a.
30. + tumour cells in B chronic lymphocytic leukemia. Blood. 91:1998;4273.
31. Van Parijs L., Biuckians A., Abbas A.K. Functional roles of Fas and Bcl-2-regulated apoptosis of T lymphocytes. J. Immunol. 160:1998;2065.
32. Moreno M.B., Memon S.A., Zacharchuk C.M. Apoptosis signaling pathways in normal T cells. Differential activity of Bcl-2 and IL-1β-converting enzyme family protease inhibitors on glucocorticoid- and Fas-mediated cytotoxicity. J. Immunol. 157:1996;3845.
33. Consoli U., El-Tounsi I., Sandoval A., Snell V., Kleine H.-D., Brown W. Differential induction of apoptosis by fludarabine monophosphate in leukemic B and normal T cells in chronic lymphocytic leukemia. Blood. 91:1998;1742.
34. Pepper C., Bentley P., Hoy T. Regulation of clinical chemoresistance by bcl-2 and bax oncoproteins in B-cell chronic lymphocytic leukaemia. Br. J. Haematol. 95:1996;513.
35. Bentley D.P., Blackmore J.A. The inhibition of DNA synthesis in chronic lymphocytic leukaemia cells by chlorambucil in vitro. Br. J. Cancer. 65:1992;171.
36. Silber R., Degar B., Costin D., Newcomb E.W., Mani M., Rosenberg C.R. et al. Chemosensitivity of lymphocytes from patients with B-cell chronic lymphocytic leukemia to chlorambucil, fludarabine, and camptothecin analogs. Blood. 84:1994;3440.
37. Molica S., Dattilo A., Giulino C., Levato D., Levato L. Increased bcl-2/bax ratio in B-cell chronic lymphocytic leukemia is associated with a progressive pattern of disease. Haematologica. 83:1998;1122.